08:00 , Feb 16, 2015 |  BC Week In Review  |  Company News

ActoGeniX, Intrexon deal

Synthetic biology company Intrexon will acquire ActoGeniX for $60 million, comprising $30 million in cash and $30 million in stock. Intrexon will gain ActoGeniX’s TopAct platform, an oral delivery technology based on living, non-pathogenic microorganisms....
02:03 , Feb 14, 2015 |  BC Extra  |  Company News

Intrexon acquires mucosal therapeutics play ActoGeniX

Synthetic biology company Intrexon Corp. (NYSE:XON) will acquire ActoGeniX N.V. (Zwijnaarde, Belgium) for $60 million. Intrexon will gain ActoGeniX's TopAct platform, an oral delivery technology based on living, non-pathogenic microorganisms, and a pipeline including two...
08:00 , Nov 10, 2014 |  BC Week In Review  |  Clinical News

AG014: Phase I data

An open-label, Belgian Phase I trial in healthy volunteers showed that oral AG014 was well tolerated. Pharmacokinetic data showed that AG014 bacteria were released at the targeted gastrointestinal regions, including the small and large intestines,...